Evidence map›Paper›PMID 26598624›Full record

ReviewJournal of clinical pathology2016

Molecular mechanisms in multiple myeloma drug resistance.

Nicholas Nikesitch, Silvia C W Ling

Erratum issuedOpen access · hybridAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Journal of clinical pathology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 51 papers.

0numbers the graph read from it
0cells of the map it votes in
51citing papers in PubMed
4.2field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

51 citing papers in PubMed, 87 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Review
  10. Article
  11. Review
  12. Review
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 1 country.

Nicholas NikesitchSchool of Medicine, University of Western Sydney, Campbelltown, New South Wales, Australia Haematology Research Group, Ingham Institute of Applied Medical Research, Liverpool, New South Wales, Australia.
Silvia C W LingHaematology Research Group, Ingham Institute of Applied Medical Research, Liverpool, New South Wales, Australia Department of Haematology, Liverpool Hospital, Liverpool, New South Wales, Australia.
Liverpool Hospital · AUWestern Sydney University · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Multiple myeloma (MM) is predominantly an incurable malignancy despite high-dose chemotherapy, autologous stem cell transplant and novel agents. MM is a genetically heterogeneous disease and the complexity increases as the disease progresses to a more aggressive stage. MM arises from a plasma cell, which produces and secretes non-functioning immunoglobulins. Most MM cells are sensitive to proteasome inhibitors (PIs), which have become the main drug in the treatment of newly diagnosed and relapsed MM. However, not all MM is sensitive to PIs. This review summarises the literature regarding molecular biology of MM with a focus on the unfolded protein response and explores how this could affect drug sensitivity and progression of disease.

Indexed as

Drug Resistance, NeoplasmAnimalsAntineoplastic AgentsBiomarkers, TumorDisease ProgressionGenetic Predisposition to DiseaseHumansMolecular Targeted TherapyMultiple MyelomaPhenotypeProteasome Endopeptidase ComplexProteasome InhibitorsSignal TransductionTreatment FailureUnfolded Protein ResponseAntineoplastic AgentsBiomarkers, TumorProteasome Endopeptidase ComplexProteasome InhibitorsCANCERHAEMATOLOGYMOLECULAR BIOLOGYMYELOMA

Identifiers

PMID26598624
PMCPMC4752637
OpenAlexW2174635591

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.